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Simple Summary: FAL1 upregulation has been reported in many types of human cancers. The
up-regulatory mechanism was identified in ovarian cancer but was not investigated in other type of
cancers. Using The Cancer Genome Atlas (TCGA) database, we identified simultaneous upregulation
of FAL1 adjacent to chromosome 1q21.3. Among 53 putative transcription factors for FAL1 and neigh-
bouring genes, we selected c-JUN and JUND as the best candidates. This simultaneous upregulation
defines molecular biological features representing RAS-driven PTC-enriched immune-related gene
sets. These findings suggest that the simultaneous upregulation might be a potential diagnostic and
therapeutic target for RAS-driven PTC.
Abstract: We investigated the regulatory mechanism of FAL1 and unravelled the molecular biologi-
cal features of FAL1 upregulation in papillary thyroid cancer (PTC). Correlation analyses of FAL1
and neighbouring genes adjacent to chromosome 1q21.3 were performed. Focal amplification was
performed using data from copy number alterations in The Cancer Genome Atlas (TCGA) database.
To identify putative transcriptional factors, PROMO and the Encyclopaedia of DNA Elements (EN-
CODE) were used. To validate c-JUN and JUND as master transcription factors for FAL1 and ECM1,
gene set enrichment analysis was performed according to FAL1 and ECM1 expression. Statistical
analyses of the molecular biological features of FAL1- and ECM1-upregulated PTCs were conducted.
FAL1 expression significantly correlated with that of neighbouring genes. Focal amplification of
chromosome 1q21.3 was observed in ovarian cancer but not in thyroid carcinoma. However, PROMO
suggested 53 transcription factors as putative common transcriptional factors for FAL1 and ECM1
simultaneously. Among them, we selected c-JUN and JUND as the best candidates based on EN-
CODE results. The expression of target genes of JUND simultaneously increased in FAL1- and
ECM1-upregulated PTCs, especially in young patients. The molecular biological features represented
RAS-driven PTC and simultaneously enriched immune-related gene sets. FAL1 and ECM1 expression
frequently increased simultaneously and could be operated by JUND. The simultaneous upregulation
might be a potential diagnostic and therapeutic target for RAS-driven PTC.
Keywords: FAL1; ECM1; thyroid neoplasm; prognosis; RAS; immunology
Cancers 2021, 13, 3223. https://doi.org/10.3390/cancers13133223 https://www.mdpi.com/journal/cancers
Cancers 2021, 13, 3223 2 of 14
1. Introduction
Papillary thyroid cancer (PTC) is the most common endocrine malignancy, and its
incidence has been increasing worldwide [1,2]. The main reason for this increase has been
attributed to the widespread application of highly sensitive ultrasound to health screen-
ings [3]. In this context, a new approach called active surveillance is being widely studied
in the clinical setting [4]. However, basic experiments and clinical studies on thyroid cancer
occurring in young patients and refractory thyroid cancer relatively commonly observed
in the elderly are also being conducted [5–8]. These efforts have led to the development
of various tyrosine kinase inhibitors, including targeted therapy for BRAFV600E, for the
clinical setting. However, owing to limited therapeutic efficacy, there remains a need for
new therapeutic agents. Unfortunately, no new emerging therapeutic targets have been
suggested [9].
Non-coding RNA (ncRNA), a molecule that is not translated into protein, is present
abundantly and performs important biological functions [10–12]. Among various ncRNAs
such as small nucleolar RNAs (snoRNAs), microRNAs (miRNAs), small interfering RNA
(siRNA), small nuclear RNA (snRNA), extracellular RNA (exRNA), piwi-interacting RNA
(piRNAs), and long ncRNAs (lncRNAs) [13,14], previous studies have shown that lncRNAs
act as tumour susceptible genes in PTC. For example, low expression of PTC susceptibility
candidate 2 (PTSC2) was observed in PTC tumours, which, in turn, affected the expression
of genes related to cell cycle and cancer [15]. The polymorphism rs944289 on PTC suscepti-
bility candidate 3 (PTSC3) was reported to predispose to PTC [16]. BRAF-activated lncRNA
(BANCR) is upregulated in PTC, thereby promoting cell proliferation through autophagy
regulation [17].
Recently, our group reported that the oncogenic activity of f ocally amplified lncRNA
on chromosome 1 (FAL1, ENSG00000228126) is attributed to the expression of genes re-
lated to the cell cycle, including transcription factor E2F transcription factor 1 (E2F1), E2F
transcription factor 2 (E2F2), and cyclin D1 in thyroid cancers [18]. In this study, we investi-
gated the mechanism underlying FAL1 upregulation in PTC and found that extracellular
matrix protein 1 (ECM1) expression was simultaneously upregulated with FAL1 expression.
In addition, we explored the biological and clinical functions of FAL1 and ECM1 and
demonstrated the significance of simultaneous expression of FAL1 and ECM1.
2. Materials and Methods
2.1. Analysis of lncRNA and mRNA Expression Using Public Databases
lncRNA expression values were collected using The Atlas of Noncoding RNAs in
Cancer (TANRIC) derived from The Cancer Genome Atlas (TCGA) RNA-seq database [19].
TANRIC provided the quantified expression level of lncRNA as read per kilobase million
(RPKM) based on the Binary Alignment/Map format File (BAM file, *.bam). Using these
datasets, the expression level of the lncRNA FAL1 was confirmed in 20 types of human can-
cer: colon adenocarcinoma (COAD; 157 cases), rectum adenocarcinoma (READ; 71 cases),
uterine corpus endometrioid carcinoma (UCEC; 316 cases), kidney chromophobe (KICH;
66 cases), ovary serous cystadenocarcinoma (OV; 412 cases), liver hepatocellular carcinoma
(LIHC; 200 cases), prostate adenocarcinoma (PRAD; 374 cases), kidney renal clear cell carci-
noma (KIRC; 448 cases), stomach adenocarcinoma (STAD; 285 cases), bladder urothelial
carcinoma (BLCA; 252 cases), lung squamous cell carcinoma (LUSC; 220 cases), kidney
renal papillary cell carcinoma (KIRP; 198 cases), cervical squamous cell carcinoma and
endocervical adenocarcinoma (CESC; 196 cases), lung adenocarcinoma (LUAD; 488 cases),
skin cutaneous melanoma (SKCM; 226 cases), breast invasive carcinoma (BRCA; 837 cases),
head and neck squamous cell carcinoma (HNSC; 426 cases), glioblastoma multiforme
(GBM; 154 cases), thyroid carcinoma (THCA; 497 cases), and brain low grade glioma (LGG;
486 case). To compare the expression values of ECM1 and ADAMTSL4 between normal
tissues and PTC, mRNA and lncRNA expression values for the normal tissue cohort were
collected from the TCGA THCA RNA-seq database and TANRIC, respectively. We also se-
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lected GSE127083 from the GEO (Gene Expression Omnibus) database as in vitro validation
set in addition to TCGA data.
2.2. Analysis of Copy Number Alteration
To determine copy number alterations in TCGA ovarian cancer (OVCA) and TCGA
THCA, Genomic Identification of Significant Targets in Cancer (GISTIC) data from the
Broad Firehose infrastructure were used [20]. GISTIC statistically calculated the copy
number alteration occurring in many patient specimens. The data were sorted based on
the genomic build hg19. The threshold used for DNA copy number amplification was 0.1,
the confidence level was 0.99, and the q-value cut-off was 0.25.
2.3. Prediction and Validation of Putative Transcription Factors
The binding site and transcription factors of FAL1 and ECM1 were predicted using
PROMO and the Encyclopaedia of DNA Elements (ENCODE), respectively. PROMO,
which used a transcription factor source from the TRANSFAC® database, predicted po-
tential transcription factor-binding sites (TFBS). The upstream 1 kb sequence of FAL1 and
ECM1 was input, and the dissimilarity rate was analysed using the default value (15%; 85%
similarity). Information related to gene regulation based on ENCODE data was verified
using the Ensembl Genome Browser. The regulatory elements of each gene were identified
using chromatin immunoprecipitation followed by sequencing (ChIP-Seq) data from EN-
CODE, and each motif score was selected by applying a p-value threshold of 0.01. Gene
set enrichment analysis (GSEA) was performed using software, version 4.1.0, combined
with Gene Ontology [21]. The normalised enrichment score (NES) calculated by GSEA
described the correlation between the gene set and the expression dataset. Permutations
were performed 1000 times according to the basic weighted enrichment statistic, and genes
were ranked according to the level of differential expression between the two groups. We
selected a set of important genes based on a p-value of ≤0.05 and a false discovery rate
(FDR) q-value of <0.25.
2.4. Statistical Analysis
Statistical analysis was performed using Prism (GraphPad Software, San Diego, CA,
USA) or SPSS, version 25.0, for Windows (IBM Corp., Armonk, NY, USA). Data are pre-
sented as mean ± SD. Statistical comparisons of continuous variables were performed
using Student’s t-test or analysis of variance, and group comparisons were performed
using χ2 test or linear association. Gene expression associations were investigated using
the Pearson correlation coefficients.
3. Results
3.1. Positive Correlation between FAL1 and ECM1 Expression in Human Cancers
Upregulation of FAL1 expression was first reported in ovarian cancer. Focal ampli-
fication of chromosome 1q21.3 is the mechanism underlying the upregulated expression
of FAL1 [22]. To validate this upregulatory mechanism in PTC, we first investigated the
expression status of FAL1 using pan-cancer data from TCGA. Among 20 types of human
cancers, COAD, READ, and UCEC did not show any expression of FAL1. However, brain
LGG, THCA, and GBM presented higher expression values than the other types of human
cancers (Figure 1A). Interestingly, the expression of FAL1 in OVCA was not higher than
that in other types of human cancers. Because the upregulated expression of genes by focal
amplification is inevitably accompanied by increased expression of genes present at the
same location on the chromosome, we identified the genes located around FAL1 (Figure 1B).
ECM1 and ADAMTS (disintegrin and metalloproteinase with thrombospondin motifs)-like
4 (ADAMTSL4) were located before and after FAL1 on Chr1:150354111-150876737. An anal-
ysis of the correlation between the expression of FAL1 and that of the neighbouring genes
was performed, and the results showed that the expression of threonyl-tRNA synthetase 2,
mitochondrial (TARS2), ECM1, ADAMTSL4, etc., in most tumours wherein FAL1 expres-
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sion was observed was positively correlated with FAL1 expression (Figure 1B). Whereas
the correlation of FAL1 with RPRD2 and TARS2 did not show strong positive correlation
coefficients in TCGA THCA (Figure S1), as shown in Figure 1C,D, the expression of ECM1
and ADAMTSL4 showed a positive correlation with FAL1 expression and was associated
with upregulated expression of FAL1 in PTC compared to that in the normal thyroid tissues.
Taken together, we postulated that FAL1 expression was coupled with the upregulated
expression of neighbouring genes such as ECM1 and ADAMTSL4.
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p < 0.01. All p-values are two-sided. 
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chromosome 1q21.3. A. FAL1 expression status of 20 types of human cancers. (B) Location of FAL1 and neighbouring genes
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3.2. Focal Amplification of the FAL1 Gene in Ovarian Cancer but Not In PTC
Our analysis for the expression of FAL1 and neighbouring genes suggested simul-
taneous upregulated expression of those genes, and we investigated the amplification
status of genes based on data of copy number alterations (CNAs) from TCGA OVCA and
TCGA THCA. As previously reported, focal amplification of 1q21.3 was clearly observed
in OVCA (Figure 2A), but no amplification signal at the same position was observed in
THCA (Figure 2B , suggesting that simultaneous upregulated expression of FAL1 and th
neighbouring genes was generated by differ nt mechanisms from focal amplification in
PTC. Supporting our idea, the comparison of 1q arm-level a plification in TCGA THCA
according to the FAL1 expression status did not show any significant difference (Table S1).
Recent efforts to understand the regulatory mechanism of lncRNA expression have empha-
sised the importance of transcription factors in the expression of other coding genes. In
line with this idea, we decided to evaluate the effective transcription factors for the pro-
moter areas of FAL1 and ECM1. To achieve our goal, we identified putative TFBS in DNA
sequences defined in TRANSFAC, using PROMO [23,24]. This virtual laboratory suggested
62 transcription factors for FAL1 and 63 transcription factors for ECM1 (Figure 2C). As
expected, most putative transcription factors overlapped in both FAL1 and ECM1 (n = 53).
Taken together, the simultane u expression of FAL1 a d ECM1 might be generated by
common transcription fac ors ra her than by gene amplification.
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from TCGA THCA. (C)Results from PROMO analysis to identify putative TFBS in DNA sequences 
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Figure 2. Analysis of focal amplification using data of copy number alterations from TCGA OVCA and TCG THCA.
(A) Results of analysis of the focal amplification in the wh le chromosome from TCGA OVCA. (B) Results of analysis
of the f cal amplification in the whole chromosome rom TCGA THCA. (C)Resul s from PROMO analysis to identify
putative TFBS in DNA sequences of the FAL1 and ECM1 genes. Abbreviations: TF, transcription factor; TFBS, transcription
factor-binding sites; TCGA, The Cancer Genome Atlas; THCA, thyro d carcinoma; OVCA, ovarian cancer. The arrows
indicate chromosome 1q21.3, which was eported as a focal amplification lesion for FAL1 upregulation in OVCA.
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3.3. JUND as a Candidate for Common Transcription Factor for FAL1 and ECM1
To select the most reliable transcription factor from TFBS, we examined the location of
TFBS on the chromosome in detail using the Encyclopaedia of DNA Elements (ENCODE),
which identifies functional elements in the human genomes [25]. In the case of RPRD2 and
TARS, PROMO suggested 66 transcription factors for RPRD2 and 70 transcription factors
for TARS2. However, unfortunately, ENCODE did not have TFBS for RPRD2 (Figure S2).
Interestingly, we observed that the TFBS of c-JUN and JUND was present in the promoter
of the ECM1 gene, and the TFBS for FOS, a binding partner, was also present (Figure 3A).
Based on this finding, we hypothesised that the expression of JUN target genes might be
increased in FAL1- and ECM1-upregulated PTC, if the expression of FAL1 and ECM1 was
increased by JUN transactivation. To validate our hypothesis, we performed GSEA by
dividing the TCGA THCA into two groups according to the FAL1 and ECM1 expression
status. The target genes of c-JUN were co-ordinately enriched in the high ECM1 group
but not in the high FAL1 group (Figure 3B). However, the target genes for JUND were
co-ordinately enriched in the high ECM1 group and showed a tendency of upregulated
expression in the high FAL1 group (Figure 3C) even though JUND expression was not
correlated with FAL1 and ECM1 expression (Figure S3). In addition, we confirmed that
the expression of the FAL1, ECM1, and FAL1 target genes was also decreased by CRISPRi
JUND in leukemia cells (Figure 3D). Although we did not verify these results from a virtual
laboratory through a wet lab-based approach, we thought that these data fully supported
our idea that simultaneous expression of FAL1 and ECM1 was generated, not by focal
amplification but by common transcription factors such as JUND.
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according to patients’ age. (A) The TFBS of JUND, c-JUN, and JUN-FOS in the promoter area of ECM1 and FAL1. (B) Ex-
pression of the transcriptional target genes of c-JUN according to ECM1 and FAL1 expression status in TCGA THCA.
(C) Expression of the transcriptional target genes of JUND according to ECM1 and FAL1 expression status in TCGA THCA.
(D) Selected target gene expressions were identified in GSE127083 RNA-seq dataset for K562 cells treated with JUND-
targeted CRISPRi. (E) FAL1 expression status according to patients’ age (F) ECM1 expression status according to patients’
age. Abbreviations: JUND, junD proto-oncogene; AP-1, transcription factor subunit; JUN, jun proto-oncogene; FOS, fos
proto-oncogene; TFBS, transcripti n factor-binding sites; TCGA, The Cancer Genome Atlas; THCA, thyroid carcinoma;
E2F1, transcription factor E2F transcripti n factor 1; E2F2, transcription factor E2F transcription factor 2; VEGFA, vascular
endothelial growth factor A; C ND1 Cyclin D1. Average values were compared using ANOVA, Student’s t-test. In the
scatter plots, data are xpressed as mean ± SD. All p-values are two-sided. * p < 0.01, ** p < 0.001.
FAL1 was first investigated in ovarian high-grade serous carcinoma (HGSC), sho ing
a different correlation pattern compared to TCGA THCA (Figure 1B). We thought this
difference might indicate a different regulatory mechanism of FAL1 upregulation according
to cancer types. As described, in HGSC, focal amplification increased FAL1 upregulation.
In the case of GBM, the regulatory mechanism was not investigated. To understand the
different regulatory mechansim in HGSC and GBM, we performed GSEA using c-JUN and
JUND target genes in HGSC and GBM. High ECM1 expression was related to coordinately
enrichment of c-JUN and JUND target genes but high FAL1 expression was not (Figure S4).
This data indicated that JUND was not involved in simutaneous up regulation of ECM1
and FAL1 in HGSC and GBM.
3.4. Clinical Relevance of the Simultaneous Expression of FAL1 and ECM1
To determine the clinical implication f the simultaneous expression of FAL1 and
ECM1, we analysed the clinicopathological features of high FAL1 and ECM1 expression
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groups. Among the results, the most interesting finding was that FAL1 and ECM1 expres-
sion was upregulated in young patients aged <45 years (Figure 3D,E). In line with this
finding, we performed GSEA to understand the differences in gene expression patterns
according to age (young vs. old age) and found that KRAS- and immune-related gene sets
were co-ordinately enriched in the young age group (<45 years old), whereas metabolism-
and epithelial–mesenchymal transition-related gene sets were co-ordinately enriched in the
old age group (≥55 years old) (Figure 4A,B). According to high FAL1 or ECM1 expression,
KRAS- and immune-related gene sets were co-ordinately enriched (Figure 4C,D). Taken
together, FAL1 and ECM1 upregulated expression was frequently observed in the young
patient group, and this upregulation might contribute to defining tumour behaviour in
the young patient group. To validate our hypothesis that simultaneous expression of FAL1
and ECM1 might be related to RAS-driven PTC, we compared the molecular biological fea-
tures of PTC according to FAL1 and ECM1 expression (Tables 1 and 2). FAL1-upregulated
PTC presented fewer mRNA clusters but more miRNA clusters. RAS mutations were
frequently detected in FAL1-upregulated PTC, whereas the frequency of BRAF mutations
was relatively low. According to the frequent RAS mutation in FAL1-upregulated PTC,
the RAS/RAF, ERK, and differentiation scores were compatible with RAS-driven PTC.
However, serine 473 phosphorylation of PKB/AKT increased in FAL1-upregulated PTC.
In the analysis of ECM1-upregulated PTC, frequent RAS mutations and a relatively low
frequency of BRAF mutations were also observed as FAL1-upregulated PTC. However,
the frequency of TERT promoter mutation increased, and the ERK score also increased
compared to that in ECM1-downregulated PTC. In summary, all these molecular biological
features might be related to the aggressive behaviour of RAS-driven tumours.
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n = 124 (%)
High Expression
n = 124 (%)
mRNA cluster number
1 12 (9.8) 59 (48.8)
<0.0001 †
2 13 (10.7) 22 (18.2)
3 32 (26.2) 5 (4.1)
4 39 (32.0) 8 (6.6)
5 26 (21.3) 27 (22.3)
miRNA cluster number
1 2 (1.6) 2 (1.6)
<0.0001 †
2 48 (39.0) 19 (15.4)
3 26 (21.1) 7 (5.7)
4 16 (13.0) 58 (47.2)
5 16 (13.0) 19 (15.4)
6 15 (12.2) 18 (14.6)
RAS mutation
Absent 122 (98.4) 89 (72.4)
<0.0001 †Present 2 (1.6) 34 (27.6)
BRAF mutation
Absent 31 (25.0) 97 (78.9)
<0.0001 †Present 93 (75.0) 26 (21.1)
TERT promoter mutation
Absent 88 (87.1) 81 (89.0)
0.688 †Present 13 (12.9) 10 (11.0)
RAS/RAF score −0.67 ± 0.49 0.21 ± 0.67 <0.0001 *
ERK score 11.37 ± 16.27 2.14 ± 20.26 0.001 *
Differentiation score −0.49 ± 0.99 0.54 ± 1.08 <0.0001 *
Akt pT308 −0.02 ± 0.64 0.06 ± 0.47 0.275 *
Akt pS473 −0.02 ± 0.47 0.09 ± 0.34 0.047 *
TCGA, The Cancer Genome Atlas; THCA, thyroid carcinoma. † p values calculated by Student’s t test; * p values
calculated by chi-square test or linear-by-linear association.




n = 124 (%)
High Expression
n = 124 (%)
mRNA cluster number
1 58 (47.9) 51 (43.2)
0.190 †
2 7 (5.8) 21 (17.8)
3 36 (29.8) 5 (4.2)
4 5 (4.1) 14 (11.9)
5 15 (12.4) 27 (22.9)
miRNA cluster number
1 3 (2.5) 3 (2.4)
0.796 †
2 16 (13.1) 22 (17.9)
3 24 (19.7) 11 (8.9)
4 46 (37.7) 51 (41.5)
5 19 (15.6) 21 (17.1)
6 14 (11.5) 15 (12.2)
RAS mutation
Absent 117 (95.1) 90 (73.2)
<0.0001 †Present 6 (4.9) 33 (26.8)
BRAF mutation
Absent 71 (57.7) 92 (74.8)
0.005 †Present 52 (42.3) 31 (25.2)





n = 124 (%)
High Expression
n = 124 (%)
TERT promoter mutation
Absent 91 (95.8) 78 (84.8)
0.011 †Present 4 (4.2) 14 (15.2)
RAS/RAF score 0.01 ± 0.81 0.07 ± 0.68 0.533 *
ERK score −5.25 ± 23.26 4.92 ± 19.35 0.001 *
Differentiation score 0.32 ± 1.37 0.39 ± 1.00 0.674 *
Akt pT308 0.09 ± 0.54 0.06 ± 0.35 0.691 *
Akt pS473 0.14 ± 0.66 0.01 ± 0.46 0.122 *
TCGA, The Cancer Genome Atlas; THCA, thyroid carcinoma. † p values calculated by Student’s t test; * p values
calculated by chi-square test or linear-by-linear association.
4. Discussion
The incidence of PTC has been increasing since the last two decades in Korea even
though there is controversy regarding the overtreatment of papillary thyroid microcar-
cinoma [3,26]. Recent clinical evidence has suggested the optimal indication of active
surveillance for this indolent carcinoma [27]. Refractory thyroid cancer is defined as a
tumour with poor response to current treatments such as surgery and radioactive iodine
therapy, and it could be managed with newly developed targeted therapy using sorafenib
and vemurafenib. However, these novel therapeutics mainly target BRAFV600E-driven
PTC. In fact, currently available drugs for RAS-driven PTCs are limited.
LncRNA has been investigated as a novel diagnostic and therapeutic target in many
types of human cancers [12]. In the case of PTCs, lncRNAs were first reported as cancer
susceptible genes such as PTCSC1, PTCSC2, and PTCSC3; following this, many interesting
papers reported various kinds of tumour-suppressive or oncogenic lncRNAs in human
PTC, such as Cancer Susceptibility 2 (CASC2), Promoter Of CDKN1A Antisense DNA
Damage Activated RNA (PANDAR), Maternally Expressed 3 (MEG3), Non-Protein-Coding
RNA, Associated With MAP Kinase Pathway And Growth Arrest (NAMA), HOX Antisense
Intergenic RNA (HOTAIR), Nuclear Enriched Abundant Transcript 1 (NEAT1), Metas-
tasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1), Antisense Noncoding
RNA in the INK4 Locus (ANRIL), Plasmacytoma Variant Translocation 1 (PVT1), and
BANCR [28–32]. Our group also reported LOC100507661 and FAL1 as potential oncogenic
lncRNAs in PTC [18,33]. In fact, FAL1 was first investigated in ovarian high-grade serous
carcinoma (HGSC). This interesting study suggested that the mechanism underlying the
upregulated expression of FAL1 was focal amplification of the chromosome-harbouring
FAL1 gene, as indicated by the name itself. FAL1 expression was closely related to the up-
regulation of E2F1, suggesting the oncogenic function of the FAL1-promoting cell cycle [22].
First, we aimed to confirm the regulatory mechanism of FAL1 in PTC by focal amplification.
However, copy number alteration data from TCGA THCA did not show any amplification
signals on chromosome 1q21.3, even though FAL1 and the neighbouring genes were highly
expressed in PTC with a highly positive correlation with each other. Based on this finding,
we prepared a virtual laboratory for the identification of TFBS in FAL1 and ECM1 promoter
sequences. Results from PROMO showed many putative transcription factors for both
FAL1 and ECM1. After the analysis using ENCODE, we selected c-JUN and JUND as
the best candidates for simultaneous expression of FAL1 and ECM1, supported by GSEA
according to the FAL1 and ECM1 expression status. In fact, ENCODE was generated by
CHIP-seq from 48 cell lines, indicating our analysis using ENCODE are based on bench
work experiments. All these analyses suggested that FAL1 upregulation in PTC might
be directed by transcription factors such as JUND but not by focal amplification of the
FAL1-located chromosome.
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In terms of clinical and biological relevance, upregulated expression of FAL1 and
ECM1 was seen in the young age group and RAS-like PTC. In fact, the old-aged group
showed more aggressive clinical features. In addition, our biological understanding is
that BRAF-like PTC is more aggressive, and currently developed novel therapeutics have
focused on BRAF-like refractory PTC [5,17]. However, in clinical settings, we have not
encountered young patients with highly aggressive clinical features and RAS-like PTC
harbouring TERT promoter mutation. Interestingly, our GSEA according to FAL1 and
ECM1 expression status showed that the upregulated expression of these genes was func-
tionally related to RAS signalling and immune-related genes. In the past, we considered
epithelial-to-mesenchymal transition (EMT) as a representative mechanism of carcino-
genesis [4,6,34–36]. However, in recent years, the importance of factors determining the
tumour microenvironment has not been revealed, and it is understood that the relationship
between tumour cells and the surrounding cells, especially immunological interaction, is
an important factor in determining the prognosis of a tumour. In line with the current
advances in tumour immunology, our data may suggest that RAS-like PTC with FAL1 and
ECM1 upregulation proceeds from carcinogenesis to aggressive PTC by an immunological
mechanism compared to classical BRAF-like PTC.
Our data did not show any statistically significant difference in clinical features, except
age. We believe that this is due to the characteristics of the TCGA THCA cohort, which
makes it difficult to reflect the clinically significant role of FAL1 and ECM1 in a limited
sample number of aggressive RAS-like PTC because the prognosis of BRAF-like PTC, which
is more frequently observed, is generally poor. However, the coordinated enrichment of
RAS signalling and immune-related genes was consistently observed in PTC harbouring
upregulated expression of FAL1 and ECM1 and PTC in young patients; we believe that this
finding will be an important reference and will serve as the basis for future studies.
5. Conclusions
In conclusion, our data suggest that FAL1 upregulation might be induced by selective
transcription factors such as JUND and could be a useful diagnostic and therapeutic marker
in aggressive RAS-like PTC, especially in young patients. Further studies that include a
large sample size should be conducted to confirm our data.
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Correlation analysis of JUND expression with FAL1, ECM1 expression in THCA. (A) Correlation of
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